Key result
This review summarizes the literature and provides recommendations for the pharmacologic management of common noncardiovascular comorbidities in patients with heart failure with reduced ejection fraction.
Why the study?
Noncardiovascular comorbidities in heart failure with reduced ejection fraction worsen outcomes and complicate management due to varying therapy safety and efficacy.
How should common noncardiovascular comorbidities be pharmacologically managed in patients with heart failure with reduced ejection fraction?
How should common noncardiovascular comorbidities be pharmacologically managed in patients with heart failure with reduced ejection fraction?
This review provides recommendations for the pharmacologic management of common noncardiovascular comorbidities in patients with HFrEF, highlighting that treatment safety and efficacy may differ from those without heart failure.
Consolidates current evidence to guide complex medication management in HFrEF; leaves open the.
Patients with heart failure with reduced ejection fraction often have one or more noncardiovascular comorbidities. The presence of concomitant disease states is associated with worse outcomes, including increased risk of mortality, decreased quality of life, and increased healthcare resource utilization. Additionally, the presence of heart failure with reduced ejection fraction complicates the management of these comorbidities, including varying safety and efficacy of therapies compared to those without heart failure. This article will review the literature on the pharmacologic management of common noncardiovascular comorbidities-including chronic obstructive pulmonary disease, depression, diabetes mellitus, gout, chronic kidney disease, and iron deficiency-in patients with heart failure with reduced ejection fraction, as well as provide recommendations for appropriate treatment selection in this population.
No takes yet. Share an insight, caveat, or question.
Gale et al. (2021) conducted a review in Heart failure with reduced ejection fraction and noncardiovascular comorbidities. Pharmacologic management of noncardiovascular comorbidities was evaluated. This review summarizes the literature and provides recommendations for the pharmacologic management of common noncardiovascular comorbidities in patients with heart failure with reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: